ORCID Profile
0000-0001-7597-2005
Current Organisations
Noakhali Science and Technology University
,
Beacon Pharmaceuticals Ltd.
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Science Alert
Date: 15-01-2019
Publisher: Visagaa Publishing House
Date: 06-11-2022
Abstract: Thrombosis-associated cardiovascular and cerebrovascular disorders are the leading causes of global mortality and morbidity this rate is alarmingly rising. A erse class of antithrombotic drugs like antiplatelet and anticoagulant agents are frequently used to manage thrombus-induced physiological consequences, including cardiovascular and cerebrovascular diseases. But these agents have reported producing a series of adverse effects on the body, including potential bleeding episodes, which makes it urgent to discover antithrombotic therapy with higher efficacy, novel mechanisms of action, and fewer side effects. Research is still going on to isolate antithrombotic agents from various natural sources, and researchers are making remarkable progress in this field. In different experimental models, medicinal plant extracts and plant-derived bioactive compounds have been documented to produce antithrombotic activity through mechanisms like conventional drugs, with minimal or no side effects. Plant extracts and their bioactive compounds (phenolics, polysaccharides, peptides, terpenes, flavonoids) have proven their efficacy as potential candidates for developing safe antithrombotic therapy in numerous i in vivo /i and i in vitro /i models. Our review aims to introduce the readers to the relationship between thrombus formation and cardiovascular diseases (CVDs), problems with traditional therapies, and the role of natural resources in managing thrombus-induced cardiovascular and cerebrovascular diseases with possible mechanisms.
Publisher: Medknow
Date: 2019
Publisher: Walter de Gruyter GmbH
Date: 25-10-2021
Abstract: Notwithstanding, proton pump inhibitors (PPIs) are one of the most excellent options for different anti-secretory therapy in terms of improved symptomatic outcomes, numerous epidemiological and cohort studies provide evidence of an association between long-term proton PPIs use and increased fracture risk among users. The present attempt aimed to summarize the effect of long-term use of PPIs on musculoskeletal systems by considering the recent claims of different research groups to understand the risk of osteopenia and osteoporosis and to determine the risk factors associated with these complications. We extracted data from various systematic reviews and meta-analyses, cross-sectional studies, prospective studies, case-control studies, cohort studies, and in-vivo and in-vitro studies to observe the consequence of long-term PPIs uses over the patient’s bone health. Recent findings suggested that long-term use of PPIs plays an introductory and cabalistic role in the development of osteoporosis mostly hip fractures by disturbing numerous biological pathways and thus able to set up a link between over-prescription of PPIs and bone loss. Frequent administration of PPIs is associated with a significantly worse outcome to bone mineral density (BMD) profile and produce a negative impression on bone health. Since, there are limited data to determine the association of PPIs use and change in BMD, recommending further studies to find out this dissertation.
Publisher: Elsevier BV
Date: 07-2021
Publisher: Elsevier BV
Date: 2022
Publisher: Elsevier BV
Date: 07-2021
Publisher: Elsevier BV
Date: 06-2022
No related grants have been discovered for Tanoy Mazumder.